Genetic and Epigenetic Alteration in Gastric Carcinogenesis

Gastric cancer (GC) is an important cause of morbidity and mortality worldwide. In addition to environmental factors, genetic factors also play an important role in GC etiology, as demonstrated by the fact that only a small proportion of individuals exposed to the known environmental risk factors develop GC. Molecular studies have provided evidence that GC arises not only from the combined effects of environmental factors and susceptible genetic variants but also from the accumulation of genetic and epigenetic alterations that play crucial roles in the process of cellular immortalization and tumorigenesis. This review is intended to focus on the recently described basic aspects that play key roles in the process of gastric carcinogenesis. Genetic variation in the genes DNMT3A, PSCA, VEGF, and XRCC1 has been reported to modify the risk of developing gastric carcinoma. Several genes have been newly associated with gastric carcinogenesis, both through oncogenic activation (MYC, SEMA5A, BCL2L12, RBP2 and BUBR1) and tumor suppressor gene inactivation mechanisms (KLF6, RELN, PTCH1A, CLDN11, and SFRP5). At the level of gastric carcinoma treatment, the HER‐2 tyrosine kinase receptor has been demonstrated to be a molecular target of therapy.

[1]  Masato Yamamoto,et al.  ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas. , 2009, Surgery.

[2]  A. Scorilas,et al.  Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. , 2010, Biochemical and biophysical research communications.

[3]  A. Buzdar,et al.  Evolving novel anti-HER2 strategies. , 2009, The Lancet. Oncology.

[4]  J. Yang,et al.  Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. , 2010, Tissue antigens.

[5]  Jun Gao,et al.  Methylation of PTCH1a gene in a subset of gastric cancers. , 2009, World journal of gastroenterology.

[6]  M. J. van de Vijver,et al.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.

[7]  D. Huntsman,et al.  Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. , 2010, Human molecular genetics.

[8]  S. Friedman,et al.  Functional role of the KLF6 tumour suppressor gene in gastric cancer. , 2009, European journal of cancer.

[9]  E. Oki,et al.  High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer , 2010, Cancer science.

[10]  J. Deursen Rb Loss Causes Cancer by Driving Mitosis Mad , 2007 .

[11]  Masato Yamamoto,et al.  Anti-ERBB2 sh-RNA Suppress Both Cell Growth and Tumor Growth in ERBB2-Overexpressing Upper Gastrointestinal Adenocarcinomas , 2009, Journal of Gastrointestinal Surgery.

[12]  H. Grabsch,et al.  HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value – Conclusions from 924 Cases of Two Independent Series , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[13]  Hui-Ping Zhao,et al.  The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer , 2009, BMC gastroenterology.

[14]  A. Jimeno,et al.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Yusuke Nakamura,et al.  Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer , 2008, Nature Genetics.

[16]  R. Seruca,et al.  C/EBPα expression is associated with homeostasis of the gastric epithelium and with gastric carcinogenesis , 2010, Laboratory Investigation.

[17]  E. Van Cutsem,et al.  Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Hongbing Shen,et al.  Genetic variation of PSCA gene is associated with the risk of both diffuse‐ and intestinal‐type gastric cancer in a Chinese population , 2010, International journal of cancer.

[19]  M. Björkholm,et al.  The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. , 2010, Gastroenterology.

[20]  L Kozma,et al.  C-myc amplification and cluster analysis in human gastric carcinoma. , 2001, Anticancer research.

[21]  E. Van Cutsem,et al.  Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Yan-shen Peng,et al.  The Expression and Clinical Significance of DNA Methyltransferase Proteins in Human Gastric Cancer , 2008, Digestive Diseases and Sciences.

[23]  J. V. van Deursen,et al.  Rb loss causes cancer by driving mitosis mad. , 2007, Cancer cell.

[24]  Carla Oliveira,et al.  Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours , 2009, Human molecular genetics.

[25]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[26]  D. Roder,et al.  The epidemiology of gastric cancer , 2002, Gastric Cancer.

[27]  F. Schmitt,et al.  Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients , 2009, British Journal of Cancer.

[28]  Q. Wei,et al.  A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer , 2006, Oncogene.

[29]  S. Berger The complex language of chromatin regulation during transcription , 2007, Nature.

[30]  Hongzheng Ren,et al.  Elevated expression of semaphorin 5A in human gastric cancer and its implication in carcinogenesis. , 2010, Life sciences.

[31]  H. Lenz,et al.  EGFR Signaling and Drug Discovery , 2010, Oncology.

[32]  J D Tucker,et al.  Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. , 1995, Nucleic acids research.

[33]  M. Taniwaki,et al.  Epigenetic silencing of RELN in gastric cancer. , 2009, International journal of oncology.

[34]  J. Ajani,et al.  Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. , 2009, American journal of translational research.

[35]  H. Grabsch,et al.  High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers , 2009, Virchows Archiv.

[36]  W. Wang,et al.  Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer , 2009, BMC Cancer.

[37]  R. Seruca,et al.  Molecular targets and biological modifiers in gastric cancer. , 2008, Seminars in diagnostic pathology.

[38]  Sen Guo,et al.  Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6. , 2010, Cancer letters.

[39]  E. Reddy,et al.  Effect of Abelson murine leukemia virus on granulocytic differentiation and interleukin-3 dependence of a murine progenitor cell line. , 1987, Oncogene.

[40]  A. Matsuda,et al.  Interaction between CD45-AP and Protein-tyrosine Kinases Involved in T Cell Receptor Signaling* , 1999, The Journal of Biological Chemistry.

[41]  H. Lenz,et al.  The dual EGFR/HER‐2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN‐38 , 2009, International journal of cancer.

[42]  C. Ihm,et al.  A regulatory polymorphism at position -309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression. , 2009, Neoplasia.

[43]  J. T. Jørgensen Targeted HER2 Treatment in Advanced Gastric Cancer , 2010, Oncology.

[44]  C. Caldas,et al.  A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. , 2003, Gastroenterology.

[45]  Wei Xie,et al.  A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinoma , 2010, BMC medicine.

[46]  J. Ross,et al.  The HER-2/neu Oncogene in Tumors of the Gastrointestinal Tract , 2001, Cancer investigation.

[47]  Alessandra Renieri,et al.  Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis , 2007, Journal of cellular physiology.

[48]  N. Lunet,et al.  The interferon gamma receptor 1 (IFNGR1) −56C/T gene polymorphism is associated with increased risk of early gastric carcinoma , 2008, Gut.

[49]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[50]  M. Fukuoka,et al.  Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification , 2010, Molecular Cancer Therapeutics.

[51]  N. Yoo,et al.  Frameshift mutations of autophagy‐related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability , 2009, The Journal of pathology.

[52]  N. Lunet,et al.  Tumor Necrosis Factor Alpha Extended Haplotypes and Risk of Gastric Carcinoma , 2008, Cancer Epidemiology Biomarkers & Prevention.

[53]  G. Sauter,et al.  HER-2 amplification is highly homogenous in gastric cancer. , 2010, Human pathology.

[54]  Stefan David,et al.  Silencing of Claudin-11 Is Associated with Increased Invasiveness of Gastric Cancer Cells , 2009, PloS one.

[55]  T. Tahara,et al.  Effect of polymorphisms in the 3′ untranslated region (3′‐UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan , 2009, Molecular carcinogenesis.

[56]  Zev A Wainberg,et al.  Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo , 2010, Clinical Cancer Research.

[57]  W. Park,et al.  Microsatellite instability occurs frequently in human gastric carcinoma. , 1994, Oncogene.

[58]  C. O'Morain,et al.  Nature meets nurture: molecular genetics of gastric cancer , 2009, Human Genetics.

[59]  S. Latour,et al.  Interactions of CD45-associated Protein with the Antigen Receptor Signaling Machinery in T-lymphocytes* , 1999, The Journal of Biological Chemistry.

[60]  M. Toyota,et al.  Elevated Dnmt3a activity promotes polyposis in Apc(Min) mice by relaxing extracellular restraints on Wnt signaling. , 2009, Gastroenterology.

[61]  F. Roviello,et al.  Gastric Cardia Carcinoma is Associated with the Promoter -77T>C Gene Polymorphism of X-Ray Cross-Complementing Group 1 (XRCC1) , 2009, Journal of Gastrointestinal Surgery.

[62]  Jian-ming Wang,et al.  Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer , 2008, Molecular carcinogenesis.

[63]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[64]  M. Kubo,et al.  Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: the Hisayama Study. , 2008, American journal of epidemiology.

[65]  G. McLean,et al.  Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling , 2002, Nature Cell Biology.